Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Amortizatization of Intangibles (2016 - 2023)

Coherus Oncology's Amortizatization of Intangibles history spans 9 years, with the latest figure at $595000.0 for Q4 2023.

  • For Q4 2023, Amortizatization of Intangibles fell 25.62% year-over-year to $595000.0; the TTM value through Dec 2023 reached $2.4 million, down 62.57%, while the annual FY2024 figure was $4.2 million, 72.79% up from the prior year.
  • Amortizatization of Intangibles for Q4 2023 was $595000.0 at Coherus Oncology, up from -$422000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $3.7 million in Q1 2022 and bottomed at -$1.4 million in Q3 2020.
  • The 5-year median for Amortizatization of Intangibles is $848000.0 (2020), against an average of $945750.0.
  • The largest annual shift saw Amortizatization of Intangibles surged 1143.18% in 2019 before it plummeted 337.06% in 2020.
  • A 5-year view of Amortizatization of Intangibles shows it stood at $613000.0 in 2019, then surged by 451.06% to $3.4 million in 2020, then crashed by 67.23% to $1.1 million in 2021, then dropped by 27.73% to $800000.0 in 2022, then dropped by 25.62% to $595000.0 in 2023.
  • Per Business Quant, the three most recent readings for CHRS's Amortizatization of Intangibles are $595000.0 (Q4 2023), -$422000.0 (Q3 2023), and $1.6 million (Q2 2023).